And its not because its categorically better. It is FDA approved, widely available, and backed by years of trial data on both weight loss and heart protection
Lean mass preservation Lean mass was relatively preserved across all dose tiers, though not perfectly
Both medicines share a broadly similar side-effect profile because both act on GLP-1 pathways
Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1
It is expected to be commercially available by 2026 or 2027, after the FDA approves the medication.
Medication delivery may look different: Unlike Wegovy, Ozempic, and Zepbound, which come in easy-to-use pen injectors, compounded versions will not be in the same delivery tool as a manufactured version